JAC Advance Access published online on June 27, 2007
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkm225
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Control of extended-spectrum ß-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy
1 Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea 2 Department of Pediatrics, Seoul National University Boramae Hospital, Seoul, Korea 3 Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea 4 Department of Pediatrics, Korea University College of Medicine, Seoul, Korea 5 Department of Pharmacy, Seoul National University Children's Hospital, Seoul, Korea 6 Seoul Medical Science Research Institute, Seoul National University Bundang Hospital, Seongnam, Korea 7 Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea
Received 25 January 2007; returned 21 March 2007; revised 27 April 2007; accepted 28 May 2007
* Correspondence address. Department of Pediatrics, Seoul National University Children's Hospital, 28 Yeongeon-dong, Jongro-gu, Seoul 110-744, Korea. Tel: +82-2-2072-3633; Fax: +82-2-745-4703; E-mail: hoanlee{at}snu.ac.kr
Objectives: This ambidirectional intervention study was performed to examine the impact of a change in antibiotic policy on extended-spectrum ß-lactamase (ESBL) prevalence in a children's hospital with a high prevalence of ESBL production among Escherichia coli and Klebsiella pneumoniae.
Methods: The use of extended-spectrum cephalosporins was restricted and use of ß-lactam/ ß-lactamase inhibitor combinations was encouraged from 2002. All strains of E. coli and K. pneumoniae isolated from sterile body fluids from 1999 to 2005 were analysed for ß-lactamase production and the prevalences of ESBL production were compared at three periods; pre-intervention (1999–2001), transitional period (2002–03) and post-intervention (2004–05).
Results: Comparing the pre- and post-intervention periods, overall piperacillin/tazobactam use increased from 2.2 to 108.0 days on antibiotics/1000 patient admission days/year (AD) (P for trend < 0.001), whereas extended-spectrum cephalosporin use decreased from 175.0 to 96.9 AD (P for trend < 0.001). Among 252 strains of E. coli (n = 128) and K. pneumoniae (n = 124), the overall prevalence of ESBL producers decreased from 39.8% (41/103) to 22.8% (18/79) (P for trend = 0.018). This decreasing trend of ESBL production was more evident for K. pneumoniae (64.1% to 25.6%; P for trend < 0.001) than E. coli (25.0% to 19.4%; P for trend = 0.514). The mortality rates of invasive disease caused by E. coli or K. pneumoniae remained unchanged.
Conclusions: The substitution of piperacillin/tazobactam for extended-spectrum cephalosporins successfully decreased the prevalence of ESBL production of K. pneumoniae and E. coli in an institute for children where ESBLs were endemic. The impact of change in antibiotic policy was more evident in K. pneumoniae than E. coli.
Key Words: cephalosporins , piperacillin/tazobactam , intervention studies
The first two authors contributed equally to the study.